Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up

Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up

Abstract Background Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 199...

Full description

Bibliographic Details
Main Authors: Amber Litzroth, Vanessa Suin, Chloé Wyndham-Thomas, Sophie Quoilin, Gaëtan Muyldermans, Thomas Vanwolleghem, Benoît Kabamba-Mukadi, Vera Verburgh, Marjorie Jacques, Steven Van Gucht, Veronik Hutse
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Public Health
Subjects:
Hepatitis C
Prevalence
Chronic hepatitis C virus infection
Seroprevalence
Direct-acting antivirals
Belgium
Online Access:http://link.springer.com/article/10.1186/s12889-018-6347-z

Internet

http://link.springer.com/article/10.1186/s12889-018-6347-z

Similar Items